EP0185078A1 - A process and an apparatus for the recovery of a polypeptide from a fermentation broth - Google Patents

A process and an apparatus for the recovery of a polypeptide from a fermentation broth

Info

Publication number
EP0185078A1
EP0185078A1 EP85903232A EP85903232A EP0185078A1 EP 0185078 A1 EP0185078 A1 EP 0185078A1 EP 85903232 A EP85903232 A EP 85903232A EP 85903232 A EP85903232 A EP 85903232A EP 0185078 A1 EP0185078 A1 EP 0185078A1
Authority
EP
European Patent Office
Prior art keywords
fermentation broth
fermentation
process according
polypeptide
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP85903232A
Other languages
German (de)
French (fr)
Inventor
John Pedersen
Kim Ry Hejnaes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordisk Gentofte AS
Original Assignee
Nordisk Gentofte AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordisk Gentofte AS filed Critical Nordisk Gentofte AS
Publication of EP0185078A1 publication Critical patent/EP0185078A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/18—External loop; Means for reintroduction of fermented biomass or liquid percolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • a process and an apparatus for the recovery of a poly ⁇ peptide from a fermentation broth A process and an apparatus for the recovery of a poly ⁇ peptide from a fermentation broth.
  • the present invention concerns a process for recovering a polypeptide from a fermentation broth.
  • Polypeptides which were previously recovered from ani ⁇ mal tissue or organs, e.g. by extraction, are now increas ⁇ ingly produced by bio-technjcal processes using micro ⁇ organisms, such as bacteria or yeast cells, transformed by engineering in a manner such as to form the desired polypeptide as a fermentation product.
  • the desired polypeptide In fermentation of a substrate by means of the transformed microorganisms the desired polypeptide is in certain cases secreted to the medium.
  • the polypeptide will occur in a low concentration, e.g. 10-200 mg/1, and will be mixed with proteolytic enzymes which have simultaneous ⁇ ly been secreted from the microorganism.
  • the fermenta- tion is usually carried out at a relatively high tempera ⁇ ture, such as from 25-40°C, with a consequent risk of pro ⁇ teolytic degradation as well as de ⁇ aturation of the poly ⁇ peptide.
  • isolation of the desired polypeptide from the fer ⁇ mentation broth is desirable - preferably by a continuous and gentle process comprising a minimum of unit operations, and so that the isolated product is present in a form which lends itself to further purification.
  • the present invention is based on the finding that the po ⁇ lypeptide can be extracted directly from the fermentation broth under specific conditions, if desired even during the very fermentation.
  • the invention concerns a process for recovering a polypeptide from a fermentation broth, said polypeptide having been formed by fermentation with a microorganism, said fermentation broth being treated with a chromato ⁇ graphic material containing hydrophobic groups and adsorb- ing the polypeptide contained in the fermentation broth, and the process is characterized by passing the fermenta ⁇ tion broth with its content of polypeptide and optional ⁇ ly also the microorganism directly through a bed of the said chromatographic material containing hydrophobic groups, and then eluting the polypeptide adsorbed on the chromatographic material with an aqueous medium which, if desired, may contain water miscible organic solvent.
  • the process is carried out as stated, it is possible, in a single step, to recover the desired polypeptide di ⁇ rectly, with a high yield and a high concentration fac ⁇ tor. Owing to its process-technical simplicity the pro ⁇ cess is very advantageous.
  • the desired polypeptide is obtained in the eluate in a high yield and great puri- ty, so that the subsequent purification can be performed without complications.
  • the fermentation broth is treated continuously with the micro ⁇ organism in a suspended state and during the very fermen ⁇ tation, the broth being circulated through the bed of the chromatographic material, expediently in a fluidized state, and recycled for further fermentation.
  • the continuous re ⁇ moval of the fermentation product i.e. the desired poly ⁇ peptide, reduces the risk of degradation, thus giving an optimum yield.
  • This effect can be intensified if the broth is kept cooled to 1-12°C, preferably 4-6°C, during the cir ⁇ culation.
  • the process of the invention has been found to be useful in the recovery to proinsulin or other insulin-like material, called ILM, from a fermentation broth formed by cultivation of a correspondingly transformed yeast cell.
  • the fermentation broth is admixed with ions having a high protein salting-out effect in a concentra ⁇ tion of 0.01 - 1 molar, preferably 0.05-0.4 molar.
  • Suitable ions are P0. 3-, SO. 2-, CCrH-U,COO NH
  • Human growth hormone, hGH has been recovered in a cor ⁇ responding manner from a fermentation broth formed by cul ⁇ tivation of a substrate with a microorganism.
  • the chromatographic material must have a suitable speci ⁇ fic affinity to the desired polypeptide.
  • chro- matographic materials suitable in connection with ILM or hGH are sepharose containing aryl or alkyl groups, e.g. octyl sepharose and phenyl sepharose.
  • ILM binds so strong ⁇ ly to these gels that it is not necessary to add ions hav ⁇ ing protein salting-out effect to the fermentation broth.
  • Phenyl sepharose is the preferred chromatographic material for the recovery of ILM since this protein binds suit ⁇ ably strongly, without rendering the subsequent elution di fficult .
  • An eluate is formed in the process of the invention, con* taining polypeptides in a concentrated form, and the de ⁇ sired polypeptide can be isolated from the eluate in a pure state in a manner known per se.
  • the invention also concerns an apparatus for carrying out the process of the invention, said apparatus being characterized by the features defined in the character-, izing portion of claim 10.
  • the apparatus comprises a fermentation container 1 which can be supplied with substrate or nutrient fluid from a supply tank 15 through a supply pipe 16. The amount of supplied nutrient fluid can be adjusted by means of a valve 16a.
  • a pipe 2 leads from the container 1 through a pump 3 to an ultrafiltration apparatus 5.
  • a conduit 6 for retentate ⁇ _aleads back to the tank 1,' and a conduit 7 for filtrate leads to two columns 8, 9 containing chromato ⁇ graphic material.
  • a (not shown) heat exchanger may be in ⁇ serted in the conduits 2 and 6 to recover heat, if the temperature in the ultrafiltration apparatus 5 has been adjusted considerably lower than the temperature of the fermentation broth in the container 1.
  • conduits 17, 19, 22 connect the contai ⁇ ner with a pump 18 and a centrifuge 20, which is provided with a drain pipe 21 for yeast concentrate.
  • the columns 8, 9 are connected with a tank 11 for equili ⁇ bration liquid or elution liquid, which can be passed to one or the other of the columns 8, 9 by adjustment of a change-over valve 12 and valves 12a and 12b.
  • a valve 13a or 13b By opening of a valve 13a or 13b, the eluate can be passed through a pipe 13 to a storage tank 14 for eluate.
  • the fermentation broth was passed through an ultrafiltra ⁇ tion system 5 of the Millipore Pellican Casette Svstem type with an 0.5 ⁇ diaphragm.
  • the retentate consisting of a concentrated suspension of the yeast cells, was re ⁇ cycled through the pipe 6 to the fermentation container 1.
  • 25 1 of a human proinsulin-producing yeast culture (Sacc- haromyces cerevisiae, AB 103-1 containing the plasmid py- BCA 5) were cultivated to an optical density of 4.3 at 37°C, measured at 610 n in the fermentation container 1.
  • the fermentation broth contained human semi-synthetic insulin in a concentration of 100 mg/1.
  • the fermentation broth including yeast cells and insulin, was passed through an ultrafiltration apparatus 5 of the Pellicon Casette System type with an 0.5 ⁇ diaphragm and recycled to the fermentation container 1.
  • the eluate from the column 8 was recycled via the conduit 10 to the fermentation container 1.
  • the above-mentioned change between the two columns 8 and 9 was repeated for a total of 4 times.
  • the overall volume in the storage tank 14 was measured to 1.2 1 with an insulin concentration of 1.8 mg/ml, corresponding to a recovery percentage of 88.
  • the yeast suspension - cultivated to an optical density of 16.6 - was applied from below and up through a 1.6 x 5 cm column, containing suspended phenyl sepharose pa rt icles to form a fluidizing bed. Amount of flow 400 ml/hour. Temperature 20°C The column had been equilibrated before ⁇ hand with 0.3 M ammonium phosphate, pH 8.0. The applica ⁇ tion was performed as a cylic process during 16 hours, and then flushing was effecting with 65 ml of an equ--.li- bration buffer. The top piston was then pressed down to the surface of the gel, and elution was performed with 100 ml of H Von0 in a direction from top toward bottom.
  • the amount of hGH present in the application liquid, flush ⁇ ing liquid and eluate were determined by RP-HPLC.
  • the application liquid contained 5 mg of BhGH, the flus ⁇ hing liquid contained 0.2 mg of BhGH, and the eluate con ⁇ tained 4.8 mg of hGH.
  • 96? ⁇ of the present hGH was thu-s: eluted in an aqueous solution without yeast cells with a con ⁇ centration factor of 5.
  • the broth was applied at 4°C to a column from Pharmacia, diameter 5.0 cm, height 15 cm, packed with phenyl sepha ⁇ rose CL 4E , equilibrated with a buffer 0.1 M (NH ⁇ ) S0 4 , adjusted to a pH of 7.2. Elution of the insulin-like ma- terial during application could not be detected. After completed application, flushing was performed with 3 co ⁇ lumn volumes of an equilibration buffer, followed by elu ⁇ tion of the insulin-like material with H consult0.
  • the yeast suspension - cultivated to an optical density of 17 - was applied from below and up through a 1.6 x 5 cm column containing suspended phenyl sepharose particles to form a fluidized bed.
  • flushing was performed with 65 ml of an equilibration buffer, and then the flow was stopped to sediment the gel.
  • the top piston was then pressed down to the surface of the gel, and a column volume of H ? 0 was applied in the direction from top toward bottom. The flow was then stopped for 30 minutes, followed by elution with 25 ml of H ? 0. The eluate was a clear, slightly yellowish insulin solu ⁇ tion without yeast cells.
  • the amount of insulin present in the application liquid and eluates was determined on RP-HPLC. In the applica ⁇ tion, 25.5 mg were bound to the column, and then the co ⁇ lumn was apparently saturated. During the flushing pro ⁇ cess an amount corresponding to 2.9 mg was detected in the eluate. Then 25.0 mg of insulin were elu ted with H-0.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Dans un procédé de récupération d'un polypeptide, tel qu'une substance analogue à l'insuline ou hGH, contenu dans un bouillon de fermentation, on fait passer le bouillon de fermentation à travers un lit d'un matériau chromatographique contenant des groupes hydrophobes, tels que la phénylsepharose. Le matériau d'insuline adsorbé est ensuite élué avec un milieu aqueux qui peut contenir, si voulu, un solvant organique miscible avec de l'eau. La séparation chromatographique dans ces conditions permet d'obtenir un grand rendement de polypeptides isolés du bouillon de fermentation et des autres composants contenus dans le bouillon par une seule étape de traitement. Il en résulte également un facteur élevé de concentration. Un appareil pour appliquer le procédé comprend un récipient de fermentation (1) et au moins une colonne chromatographique (8, 9) connectée au récipient, de même que des dispositifs (2, 7, 10) pour faire circuler le bouillon de fermentation du récipient de fermentation (1) à travers la ou les colonnes chromatographiques (8, 9).In a process for recovering a polypeptide, such as an insulin-like substance or hGH, contained in a fermentation broth, the fermentation broth is passed through a bed of chromatographic material containing hydrophobic groups , such as phenylsepharosis. The adsorbed insulin material is then eluted with an aqueous medium which may contain, if desired, an organic solvent miscible with water. Chromatographic separation under these conditions makes it possible to obtain a high yield of polypeptides isolated from the fermentation broth and from the other components contained in the broth by a single treatment step. This also results in a high concentration factor. An apparatus for carrying out the process comprises a fermentation container (1) and at least one chromatographic column (8, 9) connected to the container, as well as devices (2, 7, 10) for circulating the fermentation broth from the container fermentation (1) through the chromatographic column (s) (8, 9).

Description

A process and an apparatus for the recovery of a poly¬ peptide from a fermentation broth.
The present invention concerns a process for recovering a polypeptide from a fermentation broth.
Polypeptides, which were previously recovered from ani¬ mal tissue or organs, e.g. by extraction, are now increas¬ ingly produced by bio-technjcal processes using micro¬ organisms, such as bacteria or yeast cells, transformed by engineering in a manner such as to form the desired polypeptide as a fermentation product.
In this way it has been possible to produce biosynthe- tic insulin, hGH, interferoπ, so atotropin, prolactin and many other desired polypep ides.
In fermentation of a substrate by means of the transformed microorganisms the desired polypeptide is in certain cases secreted to the medium. Here, the polypeptide will occur in a low concentration, e.g. 10-200 mg/1, and will be mixed with proteolytic enzymes which have simultaneous¬ ly been secreted from the microorganism. The fermenta- tion is usually carried out at a relatively high tempera¬ ture, such as from 25-40°C, with a consequent risk of pro¬ teolytic degradation as well as deπaturation of the poly¬ peptide. It would therefore be desirable to isolate the polypeptide from the fermentation broth in statu nascen- di at a low temperature before the purification proper took place, but owing to the composition of the fermen¬ tation broth (high conduc ivity, presence of microorga¬ nisms) purification proper cannot be started in the known processes until the microorganisms have been removed and a buffer change has taken place. Owing to the relative¬ ly small concentrations of the desired peptide it is ne- cessary, on an industrial scale, to treat extremely large liquid volumes, so that many methods used on a smaller scale are inapplicable or too expensive.
It is known to separate the fermentation broth with the desired polypeptide from the microorganisms by centri¬ fugation, filtration or aqueous two-phase extraction. The normal procedure is then to reduce the volume to obtain a concentration of the polypeptide, enabling chromatogra¬ phic purification, such as 1 - 1 % w/v. When an optional buf¬ fer change is made as an intermediate step, purification proper can be started by either gelfitration, ion exchan¬ ge chromatography, affinity chromatography, hydrophobic chromatography or chromatofocusiπg .
All these methods are extensively used for purification of biological substances. On a large scale, however, the economy plays an important role, so the number of unit operations should be minimized.
Thus, isolation of the desired polypeptide from the fer¬ mentation broth is desirable - preferably by a continuous and gentle process comprising a minimum of unit operations, and so that the isolated product is present in a form which lends itself to further purification.
The present invention is based on the finding that the po¬ lypeptide can be extracted directly from the fermentation broth under specific conditions, if desired even during the very fermentation.
Thus, the invention concerns a process for recovering a polypeptide from a fermentation broth, said polypeptide having been formed by fermentation with a microorganism, said fermentation broth being treated with a chromato¬ graphic material containing hydrophobic groups and adsorb- ing the polypeptide contained in the fermentation broth, and the process is characterized by passing the fermenta¬ tion broth with its content of polypeptide and optional¬ ly also the microorganism directly through a bed of the said chromatographic material containing hydrophobic groups, and then eluting the polypeptide adsorbed on the chromatographic material with an aqueous medium which, if desired, may contain water miscible organic solvent.
When the process is carried out as stated, it is possible, in a single step, to recover the desired polypeptide di¬ rectly, with a high yield and a high concentration fac¬ tor. Owing to its process-technical simplicity the pro¬ cess is very advantageous. Thus, the desired polypeptide is obtained in the eluate in a high yield and great puri- ty, so that the subsequent purification can be performed without complications.
According to a preferred embodiment of the invention, the fermentation broth is treated continuously with the micro¬ organism in a suspended state and during the very fermen¬ tation, the broth being circulated through the bed of the chromatographic material, expediently in a fluidized state, and recycled for further fermentation. The continuous re¬ moval of the fermentation product, i.e. the desired poly¬ peptide, reduces the risk of degradation, thus giving an optimum yield. This effect can be intensified if the broth is kept cooled to 1-12°C, preferably 4-6°C, during the cir¬ culation.
The process of the invention has been found to be useful in the recovery to proinsulin or other insulin-like material, called ILM, from a fermentation broth formed by cultivation of a correspondingly transformed yeast cell.
Even small amounts of ILM in a very low concentration can be isolated in a yield high and with a high concentration factor, without any special requirements of the fermenta- tion medium. Thus, in the present process it has been found possible to obtain a concentration factor in excess of 100, e.g. typically 100-1000. This gives a solution of ILM which is considerably freed of the other components of the fermentation broth. In addition, application at pH<4 is possible, so that the activity of the proteoly- tic enzymes is impeded.
Appropriately, before the treatment with the chromatogra¬ phic material, the fermentation broth is admixed with ions having a high protein salting-out effect in a concentra¬ tion of 0.01 - 1 molar, preferably 0.05-0.4 molar.
Examples of suitable ions are P0. 3-, SO. 2-, CCrH-U,COO NH
Na and K . Preferred salts releasing these ions are.NH. )
2S04 and (NH4)3P04 and K-.P04, CH3C00NH4.
Human growth hormone, hGH, has been recovered in a cor¬ responding manner from a fermentation broth formed by cul¬ tivation of a substrate with a microorganism.
The chromatographic material must have a suitable speci¬ fic affinity to the desired polypeptide. Examples of chro- matographic materials suitable in connection with ILM or hGH are sepharose containing aryl or alkyl groups, e.g. octyl sepharose and phenyl sepharose. ILM binds so strong¬ ly to these gels that it is not necessary to add ions hav¬ ing protein salting-out effect to the fermentation broth. Phenyl sepharose is the preferred chromatographic material for the recovery of ILM since this protein binds suit¬ ably strongly, without rendering the subsequent elution di fficult .
An eluate is formed in the process of the invention, con* taining polypeptides in a concentrated form, and the de¬ sired polypeptide can be isolated from the eluate in a pure state in a manner known per se. The invention also concerns an apparatus for carrying out the process of the invention, said apparatus being characterized by the features defined in the character-, izing portion of claim 10.
The invention will be explained more fully below with re¬ ference to the drawing, which shows a process diagram or a system for isolation of polypeptide from a fermentation broth.
The apparatus comprises a fermentation container 1 which can be supplied with substrate or nutrient fluid from a supply tank 15 through a supply pipe 16. The amount of supplied nutrient fluid can be adjusted by means of a valve 16a. A pipe 2 leads from the container 1 through a pump 3 to an ultrafiltration apparatus 5. A conduit 6 for retentate <_aleads back to the tank 1,' and a conduit 7 for filtrate leads to two columns 8, 9 containing chromato¬ graphic material. A (not shown) heat exchanger may be in¬ serted in the conduits 2 and 6 to recover heat, if the temperature in the ultrafiltration apparatus 5 has been adjusted considerably lower than the temperature of the fermentation broth in the container 1.
To remove excess of yeast cells formed in the fermenta¬ tion container 1, conduits 17, 19, 22 connect the contai¬ ner with a pump 18 and a centrifuge 20, which is provided with a drain pipe 21 for yeast concentrate.
The columns 8, 9 are connected with a tank 11 for equili¬ bration liquid or elution liquid, which can be passed to one or the other of the columns 8, 9 by adjustment of a change-over valve 12 and valves 12a and 12b. By opening of a valve 13a or 13b, the eluate can be passed through a pipe 13 to a storage tank 14 for eluate. The invention is illustrated by means of the following examples, where examples 1 and 2 concern the operation of the embodiment of the apparatus of the invention which is shown in the drawing.
EXAMPLE 1
10 1 of human proinsulin-producing yeast culture (Saccha- romyces cerevisiae AB 103-1 containing the plasmid py-BCA 5) were cultivated to an optical density of 3.5, measured at 610 nm in the fermentation container 1.
The fermentation broth was passed through an ultrafiltra¬ tion system 5 of the Millipore Pellican Casette Svstem type with an 0.5 μ diaphragm. The retentate, consisting of a concentrated suspension of the yeast cells, was re¬ cycled through the pipe 6 to the fermentation container 1.
The filtrate, a clear yellowish liquid containing insu¬ lin-like material (c = 5 μq/tcil was transferred at 4°C through the pipe 7 to a column 8 from Pharmacia, diameter 2.5 cm, height 10 cm, packed with phenyl sepharose CL6B, equilibrated with a buffer, 0.1 M (NH, )?S0. adjusted to a pH of 8.0. The eluate from the column 8 was drained off through the pipe 13 as waste. No insulin-like material could be detected in the eluate. After the volume of the fermentation broth had been reduced to 0.5 1, the pump 3 was stopped, and the column 8 was flushed with 2 column volumes of buffer from the tank 11.
50?ό v/v ethanol u/as introduced into the tank 11, and then the column 8 was eluted with this buffer, a total of 2 column volumes. The eluate was collected in the storage tank 14.
Yield 87?ό w/w with a concentration factor of 100. EXAMPLE 2
25 1 of a human proinsulin-producing yeast culture (Sacc- haromyces cerevisiae, AB 103-1 containing the plasmid py- BCA 5) were cultivated to an optical density of 4.3 at 37°C, measured at 610 n in the fermentation container 1. The fermentation broth contained human semi-synthetic insulin in a concentration of 100 mg/1. During continuous operation and after cooling to 4°C, the fermentation broth, including yeast cells and insulin, was passed through an ultrafiltration apparatus 5 of the Pellicon Casette System type with an 0.5 μ diaphragm and recycled to the fermentation container 1.
The filtrate containing semi-synthetic human insulin in a concentration of 100 mg/1 was passed via the conduit 7 to a column 8 (2.5 x 10 cm from Pharmacia, packed with phenyl sepharose CL6B, the column having been equilibrated beforehand with a buffer, 0.05 M (NH. ),PC , pH = 8.0 at 4°C.
The eluate from the column 8 was recycled via the conduit 10 to the fermentation container 1.
After 5 hours' cyclic operation the process was repeated, now with the column 9 inserted. This column was designed and equilibrated in all respects like the column 8. The column 8 was now flushed with a volume 0.05 M (NH. ),P0 , pH 8.0, and then the bound protein was eluted with 50?ό v/v ethanol at 4°C, a total of 150 ml. The eluate was collected in the storage tank 14. The column 8 was reequi' librated as stated above.
The above-mentioned change between the two columns 8 and 9 was repeated for a total of 4 times. The overall volume in the storage tank 14 was measured to 1.2 1 with an insulin concentration of 1.8 mg/ml, corresponding to a recovery percentage of 88.
EXAMPLE 3
525 ml of Saccharomyces cerevisiae pAB18, in which 5 mg of biosynthetic human growth hormone had been dissolved, were adjusted with phosphoric acid and 25?ά ammonia water to 0.3 M and pH = 6.85.
The yeast suspension - cultivated to an optical density of 16.6 - was applied from below and up through a 1.6 x 5 cm column, containing suspended phenyl sepharose pa rt icles to form a fluidizing bed. Amount of flow 400 ml/hour. Temperature 20°C The column had been equilibrated before¬ hand with 0.3 M ammonium phosphate, pH 8.0. The applica¬ tion was performed as a cylic process during 16 hours, and then flushing was effecting with 65 ml of an equ--.li- bration buffer. The top piston was then pressed down to the surface of the gel, and elution was performed with 100 ml of H„0 in a direction from top toward bottom.
The amount of hGH present in the application liquid, flush¬ ing liquid and eluate were determined by RP-HPLC.
The application liquid contained 5 mg of BhGH, the flus¬ hing liquid contained 0.2 mg of BhGH, and the eluate con¬ tained 4.8 mg of hGH. 96?ό of the present hGH was thu-s: eluted in an aqueous solution without yeast cells with a con¬ centration factor of 5.
EXAMPLE 4
4 1 of an ILM-producing yeast culture (Saccharomyces ce¬ revisiae AB 103-1 containing the plasmid py-BCA5) were cultivated to an optical density of 3.5, measured at 610 nm . Ultrafiltration was performed on a Millipore ultrafil¬ tration equipment Pellicon Casette System with an 0.5 u diaphragm. The clear yellowish fermentation broth con¬ taining insulin-like material (c = 0.5 ^g/ml) was adjusted at 4°C to 0.1 M (NH )„S04 and adjusted to a pH of 7.2.
The broth was applied at 4°C to a column from Pharmacia, diameter 5.0 cm, height 15 cm, packed with phenyl sepha¬ rose CL 4E , equilibrated with a buffer 0.1 M (NHή) S04, adjusted to a pH of 7.2. Elution of the insulin-like ma- terial during application could not be detected. After completed application, flushing was performed with 3 co¬ lumn volumes of an equilibration buffer, followed by elu¬ tion of the insulin-like material with H„0.
Yield 85 % by weight with a concentration factor of 100.
EXAMPLE 5
200 ul of pork insulin, dissolved in 0.05 M ammonium phos¬ phate, pH = 8.2 (c = 0.94 mg/ml ) , were applied to an 0.6 x 5 cm column, packed with phenyl sepharose CL-6B FF , equilibrated with 0.05 M ammonium phosphate, pH = 8.2.
After completed application, flushing was performed with 5 column volumes of an equilibration buffer, and then the insulin was eluted with 7M urea. Yield 92 % by weight.
EXAMPLE 6
10.2 ml of fermentation broth py-BCA5 containing pork in- sulin, c = 20 ^μg/ml, were admixed with 150 μ l of H--P0. (ortho-) to pH = 2.0.
The solution was applied to an 0.6 x 5 cm column, packed with phenyl sepharose ^ CL4B, equilibrated with 0.05 M ammonium phosphate, pH = 8.2. After completed application, flushing was performed with 5 column volumes of an equilibration buffer, and then the insulin was eluted with H„0.
EXAMPLE 7
10.2 ml of fermentation broth pyBCA5 containing pork in¬ sulin, c = 10 jjg/ l, were admixed with 150 ^ul of H,P04 to pH = 2.1.
The solution was applied to an 0.6 x 5 cm column, packed with phenyl sepharose CL6B FP^, equilibrated with 0.1 M ammonium acetate, pH = 8.2.
After completed application, flushing was performed with 5 column volumes of an equilibration buffer, and then the insulin was eluted with H„0.
EXAMPLE 8
10.1 ml of fermentation broth pyBCA5 containing pork in¬ sulin, c = 10 were admixed with 150 μ l of acetic acid. pH was adjusted to 8.0 with 12.5?ό NH,.
The solution was applied to an 0.6 x 5 cm column packed with phenyl sepharose CL4B (__), equilibrated with 0.1 M po- tassium a-phosphate , pH = 8.2. After completed applica¬ tion, flushing was performed with 5 column volumes of an equilibration buffer, and then the insulin was eluted with H∑0.
EXAMPLE 9
1 mg of pork insulin dissolved in 10 ml of 0.3 M H,P0,
3 4
(-ortho), pH = 3.0 with 12.58 NH,, was applied to an 0.6 x 5 cm column packed with phenyl sepharose CL4B R, equili- brated with 0.3 M ( H4)3P04, pH = 8.0.
After completed application, flushing was performed with 5 column volumes of an equilibration buffer, and then the insulin was eluted with H_0. Yield 93?ό by weight.
EXAMPLE 10
500 ml of an ILM producing yeast culture (Saccharomyces cerevisiae pAHlδ containing the plasmid pYBCA5), in which 50.1 mg of pork insulin had been dissolved, were adjusted with phosphoric acid and 25?ό ammonia to a concentration of 0.3 M and a pH of 3.0.
The yeast suspension - cultivated to an optical density of 17 - was applied from below and up through a 1.6 x 5 cm column containing suspended phenyl sepharose particles to form a fluidized bed. The aolumn had been equilibrated beforehand in 0.3 M ammonium phosphate, pH = 8.0. Af¬ ter application, flushing was performed with 65 ml of an equilibration buffer, and then the flow was stopped to sediment the gel.
The top piston was then pressed down to the surface of the gel, and a column volume of H?0 was applied in the direction from top toward bottom. The flow was then stopped for 30 minutes, followed by elution with 25 ml of H?0. The eluate was a clear, slightly yellowish insulin solu¬ tion without yeast cells.
The amount of insulin present in the application liquid and eluates was determined on RP-HPLC. In the applica¬ tion, 25.5 mg were bound to the column, and then the co¬ lumn was apparently saturated. During the flushing pro¬ cess an amount corresponding to 2.9 mg was detected in the eluate. Then 25.0 mg of insulin were elu ted with H-0.

Claims

P a t e n t C l a i m s :
1. A process for recovering a polypeptide from a fer¬ mentation broth, said polypeptide having been formed by fermentation with a microorganism, said fermentation broth being treated with a chromatographic material containing hydrophobic groups and adsorbing the polypeptide contained in the fermentation broth, c h a r a c t e r i z e d by treating the fermentation broth, optionally after re¬ moval of the microorganism, with the said chromatographic material containing hydrophobic groups, and eluting the polypeptide adsorbed on the chromatographic material with an aqueous medium, which if desired, may contain a water miscible organic solvent.
2. A process according to claim 1, c h a r a c t e r - i z e d by continuously circulating the fermentation broth with the microorganism in a suspended state from a fer¬ mentation section through a fluidized bed of the chroma¬ tographic material, and then recycling the microorganism suspension to the fermentation section.
3. A process according to claim 1, c h a r a c t e r ¬ i z e d by circulating the fermentation broth through an ultrafiltration apparatus to separate the retentate con¬ taining the microorganism, recirculating the retentate containing the microorganism, and passing the filtrate through a bed of the chromatographic material, and, if desired, recycling it as a substrate.
4. A process according to any of claims 1-3, c h a r a c t e r i z e d in that the microorganism is a yeast cell transformed by introduction of a gene which codes for the desired polypeptide.
5. A process according to claim 4, c h a r a c t e r ¬ i z e d in that the desired polypeptide is human proinsulin.
6. A process according to claim 4, c h a r a c t e r ¬ i z e d in that the desired polypeptide is hGH.
7. A process according to any of claims 1-6, c h a r a c ¬ t e r i z e d in that the chromatographic material is phe¬ nyl sepharose, and that the eluting agent is a mixture of water and ethanol.
8. A process according to any of claims 1-7, c h a r a c - t e r i z e d by adding ions with a high protein salting- out effect in a concentration of 0.01-1 molar, preferably 0.05-0.4 molar, to the fermentation broth before the treat¬ ment with the chromatographic material.
9. A process according to claim 8, c h a r a c t e r - i z e d by adjusting the pH of the fermentation broth to
3-5.
10. A process according to any of claims 1-9, c h a r a c e r i z e d by-keeping the fermentation broth cooled to a temperature of 2-12°C, preferably 4-6°C, during the treatment with the chromatographic material.
11. An apparatus for carrying out the process according to claims 1-10, c h a r a c t e r i z e d by consisting of a fermentation container (1) and at least one chroma¬ tographic column (8, 9) connected with said container, as well as means (2, 7, 10) to circulate the fermentation broth from the fermentation container (1) through the chro¬ matographic column or columns (8, 9).
12. An apparatus according to claim 11, c h a r a c t e r i z e d by comprising an ultra iltration device (5) connected with means (6) for recycling the microorganism suspension to the fermentation container (1), and means (7) for transferring filtrate to the chromatographic co¬ lumn or columns (8, 9).
EP85903232A 1984-06-25 1985-06-25 A process and an apparatus for the recovery of a polypeptide from a fermentation broth Pending EP0185078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK309184A DK309184D0 (en) 1984-06-25 1984-06-25 PROCEDURE FOR INSULATING INSULIN OR INSULINARY MATERIALS FROM A FERMENTING FLUID
DK3091/84 1984-06-25

Publications (1)

Publication Number Publication Date
EP0185078A1 true EP0185078A1 (en) 1986-06-25

Family

ID=8118989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85903232A Pending EP0185078A1 (en) 1984-06-25 1985-06-25 A process and an apparatus for the recovery of a polypeptide from a fermentation broth

Country Status (5)

Country Link
EP (1) EP0185078A1 (en)
JP (1) JPS61502585A (en)
AU (1) AU4607985A (en)
DK (2) DK309184D0 (en)
WO (1) WO1986000339A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232531A (en) * 1963-05-13 1966-02-01 Jr Richard G Hodge Calculator
FR2660932B1 (en) * 1990-04-13 1995-03-03 Britech Sa SEMI-CONTINUOUS FERMENTATION PROCESS AND DEVICE, PARTICULARLY FOR THE MANUFACTURE OF A BIOLOGICAL MIXTURE BASED ON PROPIONIC ACID.
US6022477A (en) * 1997-11-14 2000-02-08 New Jersey Institute Of Technology Method and apparatus for isolation purification of biomolecules
FR2830188B1 (en) * 2001-09-28 2005-01-28 Oreal TINCTORIAL COMPOSITION CONTAINING A PARA-AMINOPHENOL OR PARA-PHENYLENE DIAMINE COMPOUND SUBSTITUTED WITH A SILANIC RADICAL
AU2004324756A1 (en) * 2004-11-09 2006-05-18 Usv Limited A novel process for purification of human growth harmone
BR112013013884A2 (en) * 2010-12-06 2016-09-13 Pall Corp continuous processing methods for biological products
MY180565A (en) 2011-04-14 2020-12-02 Gs Caltex Corp Apparatus and method for separating and refining product manufactured by microbial fermentation by using adsorbent
TWI637057B (en) * 2012-11-09 2018-10-01 拜爾沙納有限公司 Discontinuous fed batch processing with the use of alternating bioreactors
CN108840922A (en) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 Separate albumin non-bound, the method for albumin conjugates and small molecule compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE413986B (en) * 1973-03-23 1980-07-07 Exploaterings Ab Tbf SEE TO SEPARATE AMPHIPATIC SUBJECTS INCLUDING BOTH HYDROPHILA AND HYDROPHOBIC GROUPS AND GEL PRODUCT FOR IMPLEMENTATION OF SEPARATION
NL8201650A (en) * 1982-04-21 1983-11-16 Akzo Nv SEMISYNTHETIC PREPARATION OF HUMANE INSULIN.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8600339A1 *

Also Published As

Publication number Publication date
DK84386D0 (en) 1986-02-24
WO1986000339A1 (en) 1986-01-16
DK309184D0 (en) 1984-06-25
AU4607985A (en) 1986-01-24
JPS61502585A (en) 1986-11-13
DK84386A (en) 1986-02-24

Similar Documents

Publication Publication Date Title
US5108916A (en) Process for stereoselectively hydrolyzing, transesterifying or esterifying with immobilized isozyme of lipase from candida rugosa
Willis et al. Preparation of the periplasmic binding proteins from Salmonella typhimurium and Escherichia coli
US5593856A (en) Method for producing protein in a cell-free system
JPH0231687A (en) Purification of serum albumin
US8852435B2 (en) Purification and separation treatment assembly (PASTA) for biological products
CA1286696C (en) Automatic process for purifying physiologically active substance, apparatus for the same, and carrier with proteinaceous ligand fixed theretoto be used for the same
EP0185078A1 (en) A process and an apparatus for the recovery of a polypeptide from a fermentation broth
Kelmers et al. [1] Large-scale fermentation of Escherichia coli and recovery of transfer ribonucleic acids
US5795767A (en) Epimerase
RU2054044C1 (en) Method of preparing human recombinant gamma-interferon without n-terminal methionine
Sodek et al. Large-scale preparation and some properties of penicillopepsin, the acid proteinase of Penicillium janthinellum
Pearson et al. Preparation of crude transfer RNA and chromatographic purification of five transfer RNAs from calf liver
Lehman et al. A novel process for the large-scale purification of recombinant tick anticoagulant peptide using perfusion chromatography
RU2122549C1 (en) Chromatography method of isolation and purification of proteins, peptides and their complexes
Bernlohr et al. Formation of Activated Amino-Acids by Intact Cells of Azotobacter vinelandii
SU998502A1 (en) Process for preparing nuclease
RU2230119C1 (en) Method for preparing disaccharide
SU1693048A1 (en) Method of bilirubin oxidase preparation
SU990814A1 (en) Process for producing p-tryptophan
Kehoe The story of biosynthetic human insulin
US5702922A (en) Method for the extraction of glicentin or glicentin analogous substances
KR920008377B1 (en) Method for purification of igf-i
SU1518367A1 (en) Method of producing biomass of bacteria providencia stuartii enriched in restrictase pst 1
RU2032743C1 (en) Method for producing of yeast alcohol oxidase
SU787464A1 (en) Method of preparing ribonucleases from aspergillus clavatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19860222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19870113

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PEDERSEN, JOHN

Inventor name: HEJNAES, KIM RY